Marisa Wexler, MS,  senior science writer—

ReCode Therapeutics has raised $50 million in extended series B financing, which the company plans to use to help develop RCT2100, its experimental treatment for cystic fibrosis (CF). “We are delighted with the continued high level of interest in our novel approach to the targeted delivery of genetic…

A type of bacteria called Achromobacter, which can cause problematic lung infections in people with cystic fibrosis (CF), uses a molecular weapon — one known as a type 3 secretion system — to induce a powerful inflammatory response during infections, a new study found. “These bacteria resist the action…

CFTR — the protein whose defect or absence causes cystic fibrosis (CF) — helps cells called ionocytes remove liquid from the airways, a study shows. The finding sheds new light on the biological processes that are disrupted in CF and may have important implications for treating the disease. The…

SPL84, an experimental treatment being developed for people with cystic fibrosis (CF) that’s caused by a specific mutation, showed a good safety profile in a first clinical trial in healthy volunteers, according to its developer, SpliSense. Spurred by these positive results, SpliSense now is planning a Phase 2 clinical…

As more adults with cystic fibrosis (CF) choose to become parents, they face unique challenges in balancing the responsibilities of caring for their children and managing their disease, a study highlights. Researchers outlined several areas where care teams could be of help, such as working with prospective parents to…

A three-dimensional MRI scan of the lungs can be used to monitor responses by cystic fibrosis (CF) patients to the approved CF medication Trikafta (elexacaftor/tezacaftor/ivacaftor), a new study reports. Indeed, the new 3D technology was found to work better than traditional two-dimensional MRI scans in assessing the effects of Trikafta…

Gene therapy to deliver a modified and better working version of the CFTR protein may be more effective in treating cystic fibrosis (CF) than a gene therapy aiming to deliver higher levels of the protein, a study shows. “Gene therapy and gene editing techniques, whilst still in their infancy,…

Porosome Therapeutics is seeking a U.S. patent that would cover its “radically new and distinctive” technology platform for the treatment of cystic fibrosis (CF) and other health conditions, the company said in a press release. Its platform works by targeting a cellular structure called the porosome. The global…

Taking high-dose vitamin D supplements during acute lung infections may help to improve bone health for people with cystic fibrosis (CF). “These findings suggest that use of high-dose vitamin D supplementation during an APE [acute pulmonary exacerbation] may mitigate the bone loss suffered by people with CF with each…

An international team of scientists has published new guidelines for how best to perform exercise testing in people with cystic fibrosis (CF). “Guidance and standard operating procedures for functional exercise testing in cystic fibrosis” was published in European Respiratory Review. “Our goal is that all people…